The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Targeting DNA damage response in cancer therapy
Open accessAbstract
Cancer chemotherapy and radiotherapy are designed to kill cancer cells mostly by inducing DNA damage. DNA damage is normally recognized and repaired by the intrinsic DNA damage response machinery. If the damaged lesions are successfully repaired, the cells will survive. In order to specifically and effectively kill cancer cells by therapies that induce DNA damage, it is important to take advantage of specific abnormalities in the DNA damage response machinery that are present in cancer cells but not in normal cells. Such properties of cancer cells can provide biomarkers or targets for sensitization. For example, defects or upregulation of the specific pathways that recognize or repair specific types of DNA damage can serve as biomarkers of favorable or poor response to therapies that induce such types of DNA damage. Inhibition of a DNA damage response pathway may enhance the therapeutic effects in combination with the DNA‐damaging agents. Moreover, it may also be useful as a monotherapy when it achieves synthetic lethality, in which inhibition of a complementary DNA damage response pathway selectively kills cancer cells that have a defect in a particular DNA repair pathway. The most striking application of this strategy is the treatment of cancers deficient in homologous recombination by poly(ADP‐ribose) polymerase inhibitors. In this review, we describe the impact of targeting the cancer‐specific aberrations in the DNA damage response by explaining how these treatment strategies are currently being evaluated in preclinical or clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
The DNA Damage Response: Making It Safe to Play with Knives
Ciccia, A., & Elledge, S. J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.019 · Cited by 4,368
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation
Bakkenist, C. J., & Kastan, M. B. (2003) · Nature · doi:10.1038/nature01368 · Cited by 3,466
ATM and ATR Substrate Analysis Reveals Extensive Protein Networks Responsive to DNA Damage
Matsuoka, S., Ballif, B. A., Smogorzewska, A., McDonald, E. R., Hurov, K. E., Luo, J., Bakalarski, C. E., Zhao, Z., Solimini, N., Lerenthal, Y., et al. (2007) · Science · doi:10.1126/science.1140321 · Cited by 3,075
Sensing DNA Damage Through ATRIP Recognition of RPA-ssDNA Complexes
Zou, L., & Elledge, S. J. (2003) · Science · doi:10.1126/science.1083430 · Cited by 2,693
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
The mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Hoeijmakers, J. H. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804615 · Cited by 2,239
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Initiative, A. P. C. G., Biankin, A. V., Waddell, N., Kassahn, K. S., Gingras, M.-C., Muthuswamy, L. B., Johns, A. L., Miller, D. K., Wilson, P. J., Patch, A.-M., et al. (2012) · Nature · doi:10.1038/nature11547 · Cited by 2,058
Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions
Gorgoulis, V. G., Vassiliou, L.-V. F., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., Venere, M., DiTullio, R. A., Kastrinakis, N. G., Levy, B., et al. (2005) · Nature · doi:10.1038/nature03485 · Cited by 2,009
DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy
Olaussen, K. A., Dunant, A., Fouret, P., Brambilla, E., André, F., Haddad, V., Taranchon, E., Filipits, M., Pirker, R., Popper, H. H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060570 · Cited by 1,727
53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
Bunting, S. F., Callén, E., Wong, N., Chen, H.-T., Polato, F., Gunn, A., Bothmer, A., Feldhahn, N., Fernandez-Capetillo, O., Cao, L., et al. (2010) · Cell · doi:10.1016/j.cell.2010.03.012 · Cited by 1,671
Hallmarks of 'BRCAness' in sporadic cancers
Turner, N., Tutt, A., & Ashworth, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1457 · Cited by 1,657
ATM Activation by DNA Double-Strand Breaks Through the Mre11-Rad50-Nbs1 Complex
Lee, J.-H., & Paull, T. T. (2005) · Science · doi:10.1126/science.1108297 · Cited by 1,424
McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O'Connor, M. J., Tutt, A. N., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,310
PARP inhibition: PARP1 and beyond
Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H., & Poirier, G. G. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2812 · Cited by 1,298
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132
Gelmon, K. A., Tischkowitz, M., Mackay, H., Swenerton, K., Robidoux, A., Tonkin, K., Hirte, H., Huntsman, D., Clemons, M., Gilks, B., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70214-5 · Cited by 1,117
ATR-Mediated Checkpoint Pathways Regulate Phosphorylation and Activation of Human Chk1
Zhao, H., & Piwnica-Worms, H. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.13.4129-4139.2001 · Cited by 1,091
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086
Resistance to therapy caused by intragenic deletion in BRCA2
Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011
Bouwman, P., Aly, A., Escandell, J. M., Pieterse, M., Bartkova, J., van der Gulden, H., Hiddingh, S., Thanasoula, M., Kulkarni, A., Yang, Q., et al. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1831 · Cited by 1,001
Rottenberg, S., Jaspers, J. E., Kersbergen, A., van der Burg, E., Nygren, A. O. H., Zander, S. A. L., Derksen, P. W. B., de Bruin, M., Zevenhoven, J., Lau, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806092105 · Cited by 956
Ashworth, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0812 · Cited by 856
CDC25 phosphatases in cancer cells: key players? Good targets?
Boutros, R., Lobjois, V., & Ducommun, B. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2169 · Cited by 714
The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance
Bouwman, P., & Jonkers, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3342 · Cited by 615
Shirota, Y., Stoehlmacher, J., Brabender, J., Xiong, Y.-P., Uetake, H., Danenberg, K. D., Groshen, S., Tsao-Wei, D. D., Danenberg, P. V., & Lenz, H.-J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.23.4298 · Cited by 610
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
Jaspers, J. E., Kersbergen, A., Boon, U., Sol, W., van Deemter, L., Zander, S. A., Drost, R., Wientjens, E., Ji, J., Aly, A., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0049 · Cited by 514
Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway
Kim, H., & D'Andrea, A. D. (2012) · Genes & Development · doi:10.1101/gad.195248.112 · Cited by 508
DNA mismatch repair: Molecular mechanism, cancer, and ageing
Hsieh, P., & Yamane, K. (2008) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2008.02.012 · Cited by 464
Secondary BRCA1 Mutations in BRCA1 -Mutated Ovarian Carcinomas with Platinum Resistance
Swisher, E. M., Sakai, W., Karlan, B. Y., Wurz, K., Urban, N., & Taniguchi, T. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0088 · Cited by 457
Molecular pathogenesis of Fanconi anemia: recent progress
Taniguchi, T., & D'Andrea, A. D. (2006) · Blood · doi:10.1182/blood-2005-10-4240 · Cited by 393
Plummer, R., Jones, C., Middleton, M., Wilson, R., Evans, J., Olsen, A., Curtin, N., Boddy, A., McHugh, P., Newell, D., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1223 · Cited by 383
Bajrami, I., Frankum, J. R., Konde, A., Miller, R. E., Rehman, F. L., Brough, R., Campbell, J., Sims, D., Rafiq, R., Hooper, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2541 · Cited by 373
53BP1: pro choice in DNA repair
Zimmermann, M., & de Lange, T. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2013.09.003 · Cited by 368
Mechanisms of double-strand break repair in somatic mammalian cells
Hartlerode, A. J., & Scully, R. (2009) · Biochemical Journal · doi:10.1042/bj20090942 · Cited by 365
Mammalian Base Excision Repair: the Forgotten Archangel
Dianov, G. L., & Hübscher, U. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt076 · Cited by 363
Srivastava, M., Nambiar, M., Sharma, S., Karki, S. S., Goldsmith, G., Hegde, M., Kumar, S., Pandey, M., Singh, R. K., Ray, P., et al. (2012) · Cell · doi:10.1016/j.cell.2012.11.054 · Cited by 355
Rad52 inactivation is synthetically lethal with BRCA2 deficiency
Feng, Z., Scott, S. P., Bussen, W., Sharma, G. G., Guo, G., Pandita, T. K., & Powell, S. N. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1010959107 · Cited by 341
BCR/ABL Regulates Mammalian RecA Homologs, Resulting in Drug Resistance
Slupianek, A., Schmutte, C., Tombline, G., Nieborowska-Skorska, M., Hoser, G., Nowicki, M. O., Pierce, A. J., Fishel, R., & Skorski, T. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00357-4 · Cited by 314
BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer
Taron, M., Rosell, R., Felip, E., Mendez, P., Souglakos, J., Ronco, M. S., Queralt, C., Majo, J., Sanchez, J. M., Sanchez, J. J., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh260 · Cited by 307
ERCC1 and ERCC2 Expression in Malignant Tissues From Ovarian Cancer Patients
Dabholkar, M., Bostick-Bruton, F., Weber, C., Bohr, V. A., Egwuagu, C., & Reed, E. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.19.1512 · Cited by 305
Radiation-induced Assembly of Rad51 and Rad52 Recombination Complex Requires ATM and c-Abl
Chen, G., Yuan, S.-S. F., Liu, W., Xu, Y., Trujillo, K., Song, B., Cong, F., Goff, S. P., Wu, Y., Arlinghaus, R., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.18.12748 · Cited by 274
Human AP endonuclease 1 (APE1): From mechanistic insights to druggable target in cancer
Abbotts, R., & Madhusudan, S. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.12.006 · Cited by 248
Prevo, R., Fokas, E., Reaper, P. M., Charlton, P. A., Pollard, J. R., McKenna, W. G., Muschel, R. J., & Brunner, T. B. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.21093 · Cited by 241
HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination
Adimoolam, S., Sirisawad, M., Chen, J., Thiemann, P., Ford, J. M., & Buggy, J. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707828104 · Cited by 236
Identification of Specific Inhibitors of Human RAD51 Recombinase Using High-Throughput Screening
Huang, F., Motlekar, N. A., Burgwin, C. M., Napper, A. D., Diamond, S. L., & Mazin, A. V. (2011) · ACS Chemical Biology · doi:10.1021/cb100428c · Cited by 231
Xu, J., Li, Y., Wang, F., Wang, X., Cheng, B., Ye, F., Xie, X., Zhou, C., & Lu, W. (2013) · Oncogene · doi:10.1038/onc.2012.121 · Cited by 227
DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma
Maacke, H., Jost, K., Opitz, S., Miska, S., Yuan, Y., Hasselbach, L., Lüttges, J., Kalthoff, H., & Stürzbecher, H.-W. (2000) · Oncogene · doi:10.1038/sj.onc.1203578 · Cited by 222
Inactivation of BRCA1 and BRCA2 in Ovarian Cancer
Hilton, J. L. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.18.1396 · Cited by 218
Lok, B. H., Carley, A. C., Tchang, B., & Powell, S. N. (2013) · Oncogene · doi:10.1038/onc.2012.391 · Cited by 215
Slupianek, A., Hoser, G., Majsterek, I., Bronisz, A., Malecki, M., Blasiak, J., Fishel, R., & Skorski, T. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.12.4189-4201.2002 · Cited by 207
Cremona, C. A., & Behrens, A. (2014) · Oncogene · doi:10.1038/onc.2013.275 · Cited by 204
Anticancer therapy with checkpoint inhibitors: what, where and when?
Garrett, M. D., & Collins, I. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.02.014 · Cited by 202
Kwon, H.-C., Roh, M. S., Oh, S. Y., Kim, S.-H., Kim, M. C., Kim, J.-S., & Kim, H.-J. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl430 · Cited by 200
Peasland, A., Wang, L.-Z., Rowling, E., Kyle, S., Chen, T., Hopkins, A., Cliby, W. A., Sarkaria, J., Beale, G., Edmondson, R. J., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.243 · Cited by 195
Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair
Groselj, B., Sharma, N. L., Hamdy, F. C., Kerr, M., & Kiltie, A. E. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.21 · Cited by 184
Plummer, R., Lorigan, P., Steven, N., Scott, L., Middleton, M. R., Wilson, R. H., Mulligan, E., Curtin, N., Wang, D., Dewji, R., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2113-1 · Cited by 179
Kennedy, R. D., Chen, C. C., Stuckert, P., Archila, E. M., De la Vega, M. A., Moreau, L. A., Shimamura, A., & D’Andrea, A. D. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31245 · Cited by 175
Small Molecules, Inhibitors of DNA-PK, Targeting DNA Repair, and Beyond
Davidson, D. L., Amrein, L., Panasci, L., & Aloyz, R. S. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00005 · Cited by 163
Bartkova, J., Tommiska, J., Oplustilova, L., Aaltonen, K., Tamminen, A., Heikkinen, T., Mistrik, M., Aittomäki, K., Blomqvist, C., Heikkilä, P., et al. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2008.09.007 · Cited by 158
Sallmyr, A., Tomkinson, A. E., & Rassool, F. V. (2008) · Blood · doi:10.1182/blood-2007-07-104257 · Cited by 158
Nucleotide excision repair: new tricks with old bricks
Kamileri, I., Karakasilioti, I., & Garinis, G. A. (2012) · Trends in Genetics · doi:10.1016/j.tig.2012.06.004 · Cited by 156
Verlinden, L., Bempt, I. V., Eelen, G., Drijkoningen, M., Verlinden, I., Marchal, K., Wolf‐Peeters, C. D., Christiaens, M.-R., Michiels, L., Bouillon, R., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3545 · Cited by 149
Hannay, J. A. F., Liu, J., Zhu, Q.-S., Bolshakov, S. V., Li, L., Pisters, P. W. T., Lazar, A. J., Yu, D., Pollock, R. E., & Lev, D. C. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0636 · Cited by 138
Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response
Nishida, H., Tatewaki, N., Nakajima, Y., Magara, T., Ko, K. M., Hamamori, Y., & Konishi, T. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp593 · Cited by 135
McManus, K. J., Barrett, I. J., Nouhi, Y., & Hieter, P. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813414106 · Cited by 133
Chemosensitization of Cancer Cells by KU-0060648, a Dual Inhibitor of DNA-PK and PI-3K
Munck, J. M., Batey, M. A., Zhao, Y., Jenkins, H., Richardson, C. J., Cano, C., Tavecchio, M., Barbeau, J., Bárdos, J. I., Cornell, L., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0535 · Cited by 128
CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma
Hong, J., Hu, K., Yuan, Y., Sang, Y., Bu, Q., Chen, G., Yang, L., Li, B., Huang, P., Chen, D., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61380 · Cited by 127
BRCA1 methylation: a significant role in tumour development?
Catteau, A., & Morris, J. R. (2002) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00056-1 · Cited by 122
Noguchi, M., Yu, D. S., Hirayama, R., Ninomiya, Y., Sekine, E., Kubota, N., Andō, K., & Okayasu, R. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.094 · Cited by 122
CHK1 inhibition as a strategy for targeting fanconi anemia (FA) DNA repair pathway deficient tumors
Chen, C. C., Kennedy, R. D., Sidi, S., Look, A. T., & D’Andrea, A. D. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-24 · Cited by 115
Activation of the ATM-Snail pathway promotes breast cancer metastasis
Sun, M., Guo, X., Qian, X., Wang, H., Yang, C., Brinkman, K. L., Gonzalez, M. S., Jope, R. S., Zhou, B. P., Engler, D. A., et al. (2012) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjs048 · Cited by 114
Golding, S. E., Rosenberg, E., Adams, B. R., Wignarajah, S., Beckta, J. M., O’Connor, M. J., & Valerie, K. C. (2012) · Cell Cycle · doi:10.4161/cc.11.6.19576 · Cited by 109
Postel-Vinay, S. C., Bajrami, I., Friboulet, L., Elliott, R. J. R., Fontebasso, Y., Dorvault, N., Olaussen, K. A., André, F., Soria, J., Lord, C. J., et al. (2013) · Oncogene · doi:10.1038/onc.2013.311 · Cited by 105
Ataxia-Telangiectasia-Mutated ( ATM ) Gene in Head and Neck Squamous Cell Carcinoma
Ai, L., Vo, Q. N., Zuo, C., Li, L., Ling, W., Suen, J. Y., Hanna, E. Y., Brown, K. D., & Fan, C. (2004) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-082-3 · Cited by 104
Tobin, L. A., Robert, C., Rapoport, A. P., Gojo, I., Baer, M. R., Tomkinson, A. E., & Rassool, F. V. (2012) · Oncogene · doi:10.1038/onc.2012.203 · Cited by 103
A novel small molecule RAD51 inactivator overcomes imatinib‐resistance in chronic myeloid leukaemia
Zhu, J., Zhou, L., Wu, G., Koenig, H., Lin, X., Li, G., Qiu, X., Chen, C., Hu, C., Goldblatt, E. M., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201760 · Cited by 100
A Proteomics Analysis of Cell Signaling Alterations in Colorectal Cancer
Madoz‐Gúrpide, J., Cañamero, M., Sánchez, L., Solano, J., Alfonso, P., & Casal, J. I. (2007) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m700006-mcp200 · Cited by 97
Sultana, R., McNeill, D. R., Abbotts, R., Mohammed, M. Z., Zdzienicka, M. Z., Qutob, H. M. H., Seedhouse, C., Laughton, C. A., Fischer, P. M., Patel, P. M., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27512 · Cited by 95
Abnormal expression of BRCA1 and BRCA1-interactive DNA-repair proteins in breast carcinomas
Yoshikawa, K., Ogawa, T., Baer, R. J., Hemmi, H., Honda, K., Yamauchi, A., Inamoto, T., Ko, K., Yazumi, S., Motoda, H., et al. (2000) · International Journal of Cancer · Cited by 95
Concomitant inactivation of p53 and Chk2 in breast cancer
Sullivan, A., Yuille, M., Repellin, C., Reddy, A., Reelfs, O., Bell, A., Dunne, B., Gusterson, B. A., Osin, P., Farrell, P. J., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205207 · Cited by 91
Yang, M., Chiang, W., Chou, T., Chang, S., Chen, P., Teng, S., & Wu, K.-J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1231 · Cited by 89
Alternative pathways of non-homologous end joining (NHEJ) in genomic instability and cancer
Dueva, R., & Iliakis, G. E. (2013) · Translational Cancer Research · doi:10.21037/1152 · Cited by 83
The growing complexity of HIF-1α’s role in tumorigenesis: DNA repair and beyond
Rohwer, N., Zasada, C., Kempa, S., & Cramer, T. (2012) · Oncogene · doi:10.1038/onc.2012.510 · Cited by 80
The Relationship of Platinum Resistance and ERCC1 Protein Expression in Epithelial Ovarian Cancer
Steffensen, K. D., Waldstrøm, M., & Jakobsen, A. K. M. (2009) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e3181a12e09 · Cited by 78
Ogiwara, H., Ui, A., Shiotani, B., Zou, L., Yasui, A., & Kohno, T. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt240 · Cited by 76
CDC25 Phosphatase Inhibitors: An Update
Lavecchia, A., Giovanni, C. D., & Novellino, E. (2011) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955712798868940 · Cited by 75
DNA-PKcs Expression Predicts Response to Radiotherapy in Prostate Cancer
Bouchaert, P., Guerif, S. G., Debiais, C., Irani, J., & Fromont, G. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.02.014 · Cited by 74
RBM3-Regulated Genes Promote DNA Integrity and Affect Clinical Outcome in Epithelial Ovarian Cancer
Ehlén, Õ., Nodin, B., Rexhepaj, E., Brändstedt, J., Uhlén, M., Alvarado-Kristensson, M., Pontén, F., Brennan, D. J., & Jirström, K. (2011) · Translational Oncology · doi:10.1593/tlo.11106 · Cited by 67
PARP expression in germ cell tumours
Mego, M., Čierna, Z., Světlovská, D., Macák, D., Macháleková, K., Miskovska, V., Chovanec, M., Usakova, V., Obertová, J., Babál, P., et al. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2012-201088 · Cited by 61
Altered expression of DNA double‐strand break detection and repair proteins in breast carcinomas
Angèle, S., Treilleux, I., Bremond, A. G., Tanière, P., & Hall, J. A. (2003) · Histopathology · doi:10.1046/j.1365-2559.2003.01713.x · Cited by 57
p53 ubiquitination by Mdm2: A never ending tail?
Coutts, A. S., Adams, C., & Thangue, N. B. L. (2009) · DNA repair · doi:10.1016/j.dnarep.2009.01.008 · Cited by 56
Dzikiewicz‐Krawczyk, A. (2008) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2008.05.005 · Cited by 53
Grabauskiene, S., Bergeron, E. J., Chen, G., Chang, A. C., Lin, J., Thomas, D. G., Giordano, T. J., Beer, D. G., Morgan, M. A., & Reddy, R. M. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.09.010 · Cited by 45
PARP Inhibitors in BRCA Gene-Mutated Ovarian Cancer and Beyond
Banerjee, S. N., & Kaye, S. B. (2011) · Current Oncology Reports · doi:10.1007/s11912-011-0193-9 · Cited by 43
Aberrant Fanconi anaemia protein profiles in acute myeloid leukaemia cells
Xie, Y., de Winter, J. P., Waisfisz, Q., Nieuwint, A. W. M., Scheper, R. J., Arwert, F., Hoatlin, M. E., Ossenkoppele, G. J., Schuurhuis, G., & Joenje, H. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02450.x · Cited by 43
Kuroda, S., Urata, Y., & Fujiwara, T. (2012) · PubMed · doi:10.18926/amo/48258 · Cited by 36
Impact of PARP-1 and DNA-PK expression on survival in patients with glioblastoma multiforme
Kase, M., Vardja, M., Lipping, A., Asser, T., & Jaal, J. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.06.024 · Cited by 31
Kim, D. S., Kim, M. J., Lee, J. Y., Lee, S. M., Choi, J. E., Lee, S. Y., & Park, J. Y. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.03.011 · Cited by 25
Galamb, O. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i43.6998 · Cited by 23
Cited by
Cancer stem cells—Origins and biomarkers: Perspectives for targeted personalized therapies
Walcher, L., Kistenmacher, A.-K., Suo, H., Kitte, R., Dluczek, S., Strauß, A., Blaudszun, A.-R., Yevsa, T., Fricke, S., & Kossatz-Boehlert, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01280 · Cited by 1,007
Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?
Thota, S., Rodrigues, D. A., Crans, D. C., & Barreiro, E. J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01689 · Cited by 476
DNA Repair Pathways in Cancer Therapy and Resistance
Li, L.-Y., Guan, Y.-D., Chen, X.-S., Yang, J.-M., & Cheng, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.629266 · Cited by 383
DNA Damage/Repair Management in Cancers
Alhmoud, J. F., Woolley, J. F., Al Moustafa, A.-E., & Malki, M. I. (2020) · Cancers · doi:10.3390/cancers12041050 · Cited by 362
Radiation-induced signaling pathways that promote cancer cell survival (Review)
HEIN, A. L., OUELLETTE, M. M., & YAN, Y. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2614 · Cited by 201
Metadata
- Authors
- Hosoya, N., & Miyagawa, K.
- Venue
- Cancer Science
- Publisher
- Wiley
- Published
- 2014-03-21
- Volume
- 105
- Issue
- 4
- Pages
- 370-388
- ISSN
- 1347-9032 (ISSN-L)
- 1349-7006
- OpenAlex
- W2138263320
- Cited by
- 294
- References
- 105
- FWCI
- 9.25
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.